S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:LPTX

Leap Therapeutics Stock Forecast, Price & News

$2.54
+0.22 (+9.48%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$2.27
$2.55
50-Day Range
$1.93
$4.01
52-Week Range
$1.33
$4.17
Volume
1.99 million shs
Average Volume
2.24 million shs
Market Capitalization
$224.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.3
30 days | 90 days | 365 days | Advanced Chart
Receive LPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Leap Therapeutics logo

About Leap Therapeutics

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Headlines

Leap Therapeutics (NASDAQ:LPTX) Earns Buy Rating from HC Wainwright
November 15, 2021 |  americanbankingnews.com
3 Biotech Stocks That Surged in September
October 5, 2021 |  finance.yahoo.com
Why Leap Therapeutics Shares Are Trading Higher Today
September 16, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPTX
Fax
N/A
Employees
30
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$1.32 per share

Profitability

Net Income
$-27.51 million
Net Margins
-2,433.93%
Pretax Margin
-2,434.07%

Debt

Price-To-Earnings

Miscellaneous

Free Float
73,224,000
Market Cap
$224.33 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
11/28/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/11/2022

MarketRank

Overall MarketRank

2.09 out of 5 stars

Medical Sector

497th out of 1,391 stocks

Pharmaceutical Preparations Industry

232nd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

Is Leap Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Leap Therapeutics stock.
View analyst ratings for Leap Therapeutics
or view top-rated stocks.

How has Leap Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Leap Therapeutics' stock was trading at $2.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LPTX stock has increased by 26.4% and is now trading at $2.54.
View which stocks have been most impacted by COVID-19
.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, March 11th 2022.
View our earnings forecast for Leap Therapeutics
.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) released its earnings results on Friday, November, 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.03. Leap Therapeutics had a negative net margin of 2,433.93% and a negative trailing twelve-month return on equity of 63.02%.
View Leap Therapeutics' earnings history
.

What price target have analysts set for LPTX?

4 brokerages have issued 12 month price objectives for Leap Therapeutics' shares. Their forecasts range from $4.00 to $6.00. On average, they anticipate Leap Therapeutics' stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 77.2% from the stock's current price.
View analysts' price targets for Leap Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the following people:
  • Doug E. Onsi, President, CEO, CFO, Secretary & Treasurer
  • Augustine J. Lawlor, Chief Operating Officer
  • Cynthia Sirard, Chief Medical Officer
  • Michael Haas, Head-Research
  • Jason S. Baum, Vice President & Head-Translational Medicine

What other stocks do shareholders of Leap Therapeutics own?

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Artal Group S.A. (6.70%), Deerfield Management Company L.P. Series C (6.70%), Rock Springs Capital Management LP (5.88%), Tang Capital Management LLC (4.19%), Tri Locum Partners LP (3.03%) and Platinum Investment Management Ltd. (2.22%).
View institutional ownership trends for Leap Therapeutics
.

Which major investors are selling Leap Therapeutics stock?

LPTX stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., BlackRock Inc., Citadel Advisors LLC, and McAdam LLC.
View insider buying and selling activity for Leap Therapeutics
or view top insider-selling stocks.

Which major investors are buying Leap Therapeutics stock?

LPTX stock was acquired by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Rock Springs Capital Management LP, Tang Capital Management LLC, Tri Locum Partners LP, Artal Group S.A., Renaissance Technologies LLC, EAM Investors LLC, and EAM Global Investors LLC.
View insider buying and selling activity for Leap Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $2.54.

How much money does Leap Therapeutics make?

Leap Therapeutics has a market capitalization of $224.33 million and generates $1.50 million in revenue each year. The company earns $-27.51 million in net income (profit) each year or ($0.47) on an earnings per share basis.

How many employees does Leap Therapeutics have?

Leap Therapeutics employs 30 workers across the globe.

What is Leap Therapeutics' official website?

The official website for Leap Therapeutics is www.leaptx.com.

Where are Leap Therapeutics' headquarters?

Leap Therapeutics is headquartered at 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at (617) 714-0360 or via email at [email protected].


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.